Guardion Health Sciences Announces Corporate Milestones Designed to Strengthen Financial Results and Improve Customer and Investor Engagement
October 14 2021 - 08:00AM
Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the
“Company”), a clinical nutrition and diagnostics company that
develops and markets clinically supported nutrition, medical foods,
supplements, and medical devices, announces today two key
initiatives designed to both improve the customer experience and
engagement, as well as to reduce costs throughout the Company.
Guardion has entered into an agreement to
terminate the lease on its San Diego, California corporate office
and main warehouse facility, which was utilized primarily for the
Company’s ocular products business. This agreement will take effect
at the end of October and is expected to reduce Guardion’s overhead
costs. Guardion is currently in the process of moving its product
inventory to a third-party logistics provider. In addition, the
Company has launched a new and improved corporate and investor
website to better engage with its investors, customers and other
stakeholders. The website can be accessed at its current URL,
www.guardionhealth.com.
“We continue to evaluate our current activities
and how we can maximize customer engagement and increase sales,
with a particular focus on the recently-acquired Viactiv business,
while also carefully and prudently managing our cost structure, in
order to create optimal shareholder value,” said Bret Scholtes,
Guardion’s CEO. “By addressing these fundamental issues, we will
continue our efforts to move Guardion towards becoming a key player
in the clinical nutrition market.”
About Guardion Health Sciences,
Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI),
is a clinical nutrition and diagnostics company. Guardion’s
portfolio of science-based, clinically supported nutrition, medical
foods, and diagnostic products support healthcare professionals,
their patients, and consumers in achieving health goals. Guardion’s
commercial and developmental initiatives are supported by equally
impressive scientific and medical advisory boards, led by seasoned
business executives and physicians with many years of experience.
This combination of expertise and scientific knowledge forms the
foundation of Guardion’s growing position within the eye care
industry and the clinical nutrition marketplace. Information and
risk factors with respect to Guardion and its business, including
its ability to successfully develop and commercialize its
proprietary products and technologies, may be obtained in the
Company’s filings with the U. S. Securities and Exchange Commission
(the “SEC”) at www.sec.gov.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but are not limited to, the Company’s ability
to raise sufficient financing to implement its business plan, the
integration of a new management team, the integration of one or
more acquisitions and targets, the impact of the COVID-19 pandemic
on the Company’s business, operations and the economy in general,
the Company’s ability to successfully develop and commercialize its
proprietary products and technologies, and the Company’s ability to
maintain compliance with Nasdaq’s listing requirements. Readers are
cautioned not to place undue reliance on these forward-looking
statements, as actual results could differ materially from those
described in the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company’s filings with the SEC, which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations Contact:CORE
IRScott Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2023 to Mar 2024